Investor Presentaiton
Novo Nordisk Annual Report 2023
Product overview¹
DIABETES
Introducing Novo Nordisk Strategic Aspirations
Risks
Management
Consolidated statements
Additional information
101
OBESITY
New-generation insulin and combinations
⚫ TresibaⓇ, insulin degludec
⚫ RyzodegⓇ, insulin degludec/insulin aspart
Fiasp®, fast-acting insulin aspart
⚫XultophyⓇ2, insulin degludec/liraglutide
Modern insulin
•
Levemir, insulin detemir
NovoRapid, insulin aspart
⚫ NovoMix® 30, biphasic insulin aspart
NovoMix® 50, biphasic insulin aspart
NovoMix® 70, biphasic insulin aspart4
Human insulin
•Insulatard® isophane (NPH) insulin
•
Actrapid, regular human insulin
⚫ Mixtard® 30, biphasic human insulin
⚫ Mixtard® 40, biphasic human insulin
⚫ Mixtard® 50, biphasic human insulin
Glucagon-like peptide-1
Victoza, liraglutide
⚫ OzempicⓇ, semaglutide
.
RybelsusⓇ, oral semaglutide
Pre-filled delivery systems
⚫FlexTouch®, U100, U200
• FlexPenⓇ
Durable delivery systems
• NovoPen® 6
• NovoPen® 5
• NovoPen® 4
• NovoPen Echo® Plus
⚫ NovoPen Echo®
Other delivery systems
.
PumpCart®, NovoRapidⓇ and FiaspⓇ cartridge
to be used in pump
• Penfill® cartridge
• MallyaⓇ
Oral antidiabetic agents
•
Novo NormⓇ, repaglinide
Glucagon
•
GlucaGen®, glucagon (vial and HypokitⓇ)
•
Zegalogue, dasiglucagon
Needles
• NovoFine® Plus
⚫ NovoFine®
• NovoTwist®
• NovoFineⓇ AutoCover®
Glucagon-like peptide-1
• SaxendaⓇ, liraglutide 3.0 mg
.
WegovyⓇ, semaglutide 2.4 mg
Obesity delivery systems
Saxenda, FlexTouch®
Wegovy Single Dose Device and FlexTouch®
.
• InnoLetⓇ
• Ozempic®, FlexTouch®
RARE DISEASE
Rare blood disorders
⚫ NovoSevenⓇ, eptacog alfa (recombinant activated factor VII)
⚫ NovoEight®5, turoctocog alfa (recombinant factor VIII)
• NovoThirteen®, catridecacog (recombinant factor XIII)
⚫ RefixiaⓇ6, nonacog beta pegol, N9-GP (recombinant factor IX)
.
Esperoct, turoctocog alfa pegol, N8-GP (recombinant factor VIII)
Alhemo®, concizumab (anti-TFPI)
Rare endocrine disorders
⚫ NorditropinⓇ, somatropin (rDNA origin)
• Sogroya®, somapacitan (rDNA origin)
Pre-filled human growth hormone delivery systems
• FlexPro®
• NordiFlex®
Other delivery systems
• PenMate®, automatic needle inserter for NordiFlex®
•
Hormone replacement therapies
VagifemⓇ7, estradiol hemihydrate
• Activelle®, estradiol/norethisterone acetate
⚫ KliogestⓇ, estradiol/norethisterone acetate
⚫ NovofemⓇ, estradiol/norethisterone acetate
• Trisequens®, estradiol/norethisterone acetate
• EstrofemⓇ, estradiol
1. Products listed may not be available in all markets. 2. In the US approved under the brand name Xultophy 100/3.6. 3. In the US called Novo Log. 4. The global discontinuation of NovoMix 70 and Mixtard® 40 has been communicated. 5. In the US written Novoeight. 6. In the US approved under the name of REBINYN®. 7. In the UK also called gina®.View entire presentation